TMPRSS2 Is a Host Factor That Is Essential for Pneumotropism and Pathogenicity of H7N9 Influenza A Virus in Mice

ABSTRACT Cleavage of the hemagglutinin (HA) by host proteases is essential for the infectivity of influenza viruses. Here, we analyzed the role of the serine protease TMPRSS2, which activates HA in the human respiratory tract, in pathogenesis in a mouse model. Replication of the human H7N9 isolate A/Anhui/1/13 and of human H1N1 and H3N2 viruses was compared in TMPRSS2 knockout (TMPRSS2 −/−) and wild-type (WT) mice. Knockout of TMPRSS2 expression inhibited H7N9 influenza virus replication in explants of murine tracheas, bronchi, and lungs. H1N1 virus replication was also strongly suppressed in airway explants of TMPRSS2 −/− mice, while H3N2 virus replication was only marginally affected. H7N9 and H1N1 viruses were apathogenic in TMPRSS2 −/− mice, whereas WT mice developed severe disease with mortality rates of 100% and 20%, respectively. In contrast, all H3N2 infected TMPRSS2 −/− and WT mice succumbed to lethal infection. Cleavage analysis showed that H7 and H1 are efficiently activated by TMPRSS2, whereas H3 is less susceptible to the protease. Our data demonstrate that TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 and H1N1 influenza virus in mice. In contrast, replication of H3N2 virus appears to depend on another, not yet identified protease, supporting the concept that human influenza viruses differ in protease specificity. IMPORTANCE Cleavage of the hemagglutinin (HA) by host proteases is essential for the infectivity of influenza virus, but little is known about its relevance for pathogenesis in mammals. Here, we show that knockout mice that do not express the HA-activating protease TMPRSS2 are resistant to pulmonary disease with lethal outcome when infected with influenza A viruses of subtypes H7N9 and H1N1, whereas they are not protected from lethal H3N2 virus infection. These findings demonstrate that human influenza viruses differ in protease specificity, and that expression of the appropriate protease in respiratory tissues is essential for pneumotropism and pathogenicity. Our observations also demonstrate that HA-activating proteases and in particular TMPRSS2 are promising targets for influenza therapy.

[1]  Y. Guan,et al.  The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. , 2014, The Journal of infectious diseases.

[2]  P. Nelson,et al.  Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice , 2013, PLoS pathogens.

[3]  Stefanie Gierer,et al.  Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research , 2013, Antiviral Research.

[4]  A. Gruber,et al.  The Novel Human Influenza A(H7N9) Virus Is Naturally Adapted to Efficient Growth in Human Lung Tissue , 2013, mBio.

[5]  T. Kuiken,et al.  Novel avian-origin influenza A (H7N9) virus attaches to epithelium in both upper and lower respiratory tract of humans. , 2013, The American journal of pathology.

[6]  A. Kato,et al.  TMPRSS2 Is an Activating Protease for Respiratory Parainfluenza Viruses , 2013, Journal of Virology.

[7]  Dayan Wang,et al.  Monitoring Avian Influenza A(H7N9) Virus through National Influenza-like Illness Surveillance, China , 2013, Emerging infectious diseases.

[8]  Guohua Deng,et al.  H7N9 Influenza Viruses Are Transmissible in Ferrets by Respiratory Droplet , 2013, Science.

[9]  Y. Guan,et al.  Infectivity, Transmission, and Pathology of Human-Isolated H7N9 Influenza Virus in Ferrets and Pigs , 2013, Science.

[10]  T. Tumpey,et al.  Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice , 2013, Nature.

[11]  Noriko Kishida,et al.  Characterization of H7N9 influenza A viruses isolated from humans , 2013, Nature.

[12]  Weizhong Yang,et al.  Biological features of novel avian influenza A (H7N9) virus , 2013, Nature.

[13]  Huachen Zhu,et al.  Pathogenicity of the Novel A/H7N9 Influenza Virus in Mice , 2013, mBio.

[14]  P. Collins,et al.  Receptor binding by an H7N9 influenza virus from humans , 2013, Nature.

[15]  Yu Wang,et al.  Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses , 2013, The Lancet.

[16]  W. Garten,et al.  Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. , 2013, The Biochemical journal.

[17]  Wenjun Song,et al.  Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome , 2013, The Lancet.

[18]  G. Whittaker,et al.  Cleavage Activation of Human-adapted Influenza Virus Subtypes by Kallikrein-related Peptidases 5 and 12* , 2013, The Journal of Biological Chemistry.

[19]  D. Steinhauer,et al.  Influenza HA Subtypes Demonstrate Divergent Phenotypes for Cleavage Activation and pH of Fusion: Implications for Host Range and Adaptation , 2013, PLoS pathogens.

[20]  H. Klenk,et al.  Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. , 2012, Vaccine.

[21]  Y. Guan,et al.  Matriptase, HAT, and TMPRSS2 Activate the Hemagglutinin of H9N2 Influenza A Viruses , 2012, Journal of Virology.

[22]  H. Klenk,et al.  Aprotinin and similar protease inhibitors as drugs against influenza. , 2011, Antiviral research.

[23]  J. P. Hobson,et al.  Expression and Genetic Loss of Function Analysis of the HAT/DESC Cluster Proteases TMPRSS11A and HAT , 2011, PloS one.

[24]  J. Teifke,et al.  H9 avian influenza reassortant with engineered polybasic cleavage site displays a highly pathogenic phenotype in chicken. , 2011, The Journal of general virology.

[25]  K. Klingel,et al.  Differential host determinants contribute to the pathogenesis of 2009 pandemic H1N1 and human H5N1 influenza A viruses in experimental mouse models. , 2011, The American journal of pathology.

[26]  Y. Sakoda,et al.  H9N2 influenza virus acquires intravenous pathogenicity on the introduction of a pair of di-basic amino acid residues at the cleavage site of the hemagglutinin and consecutive passages in chickens , 2011, Virology Journal.

[27]  D. A. Stein,et al.  Inhibition of Influenza Virus Infection in Human Airway Cell Cultures by an Antisense Peptide-Conjugated Morpholino Oligomer Targeting the Hemagglutinin-Activating Protease TMPRSS2 , 2010, Journal of Virology.

[28]  K. Schughart,et al.  TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells , 2010, Journal of Virology.

[29]  G. Whittaker,et al.  Modifications to the Hemagglutinin Cleavage Site Control the Virulence of a Neurotropic H1N1 Influenza Virus , 2010, Journal of Virology.

[30]  H. Klenk,et al.  MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. , 2009, Vaccine.

[31]  M. Rubin,et al.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice. , 2009, European urology.

[32]  Semi Kim,et al.  Proteolytic Activation of the 1918 Influenza Virus Hemagglutinin , 2009, Journal of Virology.

[33]  H. Klenk,et al.  Cleavage Activation of the Influenza Virus Hemagglutinin and Its Role in Pathogenesis , 2008 .

[34]  M. Takeda,et al.  Efficient Multiplication of Human Metapneumovirus in Vero Cells Expressing the Transmembrane Serine Protease TMPRSS2 , 2008, Journal of Virology.

[35]  M. Matsumura,et al.  The androgen‐regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma , 2008, The Journal of pathology.

[36]  H. Yamada,et al.  Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. , 2007, Current pharmaceutical design.

[37]  H. Klenk,et al.  Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT from Human Airway Epithelium , 2006, Journal of Virology.

[38]  P. Nelson,et al.  Phenotypic Analysis of Mice Lacking the Tmprss2-Encoded Protease , 2006, Molecular and Cellular Biology.

[39]  H. Klenk,et al.  The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Fassnacht,et al.  The adrenal secretory serine protease AsP is a short secretory isoform of the transmembrane airway trypsin-like protease. , 2004, Endocrinology.

[41]  J. Chao,et al.  Regulation of the Epithelial Sodium Channel by Serine Proteases in Human Airways* , 2002, The Journal of Biological Chemistry.

[42]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[43]  D. Steinhauer,et al.  Role of hemagglutinin cleavage for the pathogenicity of influenza virus. , 1999, Virology.

[44]  H. Goto,et al.  A novel mechanism for the acquisition of virulence by a human influenza A virus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Y. Kawaoka,et al.  Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses , 1994, Journal of virology.

[46]  B. Murphy,et al.  A single amino acid in the PB2 gene of influenza A virus is a determinant of host range , 1993, Journal of virology.

[47]  M. Vey,et al.  Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin‐like endoprotease. , 1992, The EMBO journal.

[48]  H. Klenk,et al.  Synergistic role of staphylococcal proteases in the induction of influenza virus pathogenicity. , 1987, Virology.

[49]  H. Klenk,et al.  Activation of influenza A viruses by trypsin treatment. , 1975, Virology.

[50]  P. Choppin,et al.  Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. , 1975, Virology.